PM
MITO

Prosight Management’s Stealth BioTherapeutics Corp. ADS MITO Stock Holding History

Prosight Management’s Portfolio MITO Stock Details MITO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-256,044
Closed -$346K – 59
2020
Q3 		$346K Sell
256,044
-35,100
-12% -$60.1K 0.16% 45
2020
Q2 		$533K Sell
291,144
-45,023
-13% -$82K 0.23% 48
2020
Q1 		$417K Buy
+336,167
New +$748K 0.19% 41

Other funds holding MITO

Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BBHC
Brown Brothers Harriman & Co New York $22.8B AUM 25.09% 1-Year Est. Return
Mercer Global Advisors
Mercer Global Advisors Denver, Colorado $80.9B AUM 26.08% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
TSS
Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Prosight Management's MITO Position: Q4 2020 in Review

Prosight Management sold out of Stealth BioTherapeutics Corp. ADS (MITO) in Q4 2020, closing a stake of 256,044 shares — an estimated $346K sold.

Prosight Management first reported a position in MITO in Q1 2020 and held it in 3 quarters. The position peaked at $533K in Q2 2020. 13 funds tracked by Wall St. Rank hold MITO as of Q4 2020.

  • Prosight Management reported no remaining Stealth BioTherapeutics Corp. ADS position as of Q4 2020 after selling out during the quarter.
  • Prosight Management sold 256,044 Stealth BioTherapeutics Corp. ADS shares in Q4 2020, an estimated $346K.
  • Prosight Management first reported a position in Stealth BioTherapeutics Corp. ADS in Q1 2020 and held it in 3 quarters.
  • Prosight Management's Stealth BioTherapeutics Corp. ADS position peaked at $533K in Q2 2020.
  • 13 funds tracked by Wall St. Rank held Stealth BioTherapeutics Corp. ADS as of Q4 2020.

Based on Prosight Management's 13F filing for Q4 2020, filed 12 Feb 2021.